BIOMAT Database Logo BIOMAT Database Logo

Higher lipoprotein-associated phospholipase A2 levels are associated with coronary atherosclerosis documented by coronary angiography. 2012

Tomotaka Dohi, and Katsumi Miyauchi, and Ryunosuke Ohkawa, and Kazuhiro Nakamura, and Shuta Thuboi, and Manabu Ogita, and Tadashi Miyazaki, and Akihisa Nishino, and Ken Yokoyama, and Takeshi Kurata, and Yutaka Yatomi, and Hiroyuki Daida
Department of Cardiovascular Medicine, Juntendo University School of Medicine, 2-1-1 Hongo, Tokyo 113-0033, Japan. tdohi@juntendo.ac.jp

BACKGROUND Lipoprotein-associated phospholipase A2 (Lp-PLA2) has been proposed as an inflammatory marker of cardiovascular disease. The present study investigates associations between Lp-PLA2 and other important biomarkers in Japanese patients with coronary artery disease. METHODS We measured Lp-PLA2 levels in 141 consecutive patients (age 62.6 ± 3.8 years; men 69.2%) with angiographic evidence of coronary artery disease (acute coronary syndrome [ACS]; n = 38), stable angina pectoris (SAP; n = 72) or with angiographically normal coronary arteries (NCA; n = 31). RESULTS Levels of Lp-PLA2 significantly correlated with low-density lipoprotein-cholesterol (r = 0.302), homocysteine (r = 0.528) and paraoxonase (r = 0.401) in all patients (all P < 0.01). Levels of Lp-PLA2 were significantly higher in patients with coronary atherosclerosis (ACS and SAP) than with NCA (P < 0.05). Levels of highly sensitive C-reactive protein were significantly higher in patients with ACS than with SAP and NCA (both P < 0.05). Multivariate logistic regression analyses revealed that higher Lp-PLA2 levels were independently associated with coronary atherosclerosis (odds ratio: 1.058; 95% confidence interval: 1.012-1.121; P = 0.001). CONCLUSIONS Higher Lp-PLA2 levels are associated with coronary atherosclerosis independently of traditional coronary risk factors. Thus, Lp-PLA2 is a novel biomarker of coronary atherosclerosis in Japanese patients.

UI MeSH Term Description Entries
D007564 Japan A country in eastern Asia, island chain between the North Pacific Ocean and the Sea of Japan, east of the Korean Peninsula. The capital is Tokyo. Bonin Islands
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D003324 Coronary Artery Disease Pathological processes of CORONARY ARTERIES that may derive from a congenital abnormality, atherosclerotic, or non-atherosclerotic cause. Arteriosclerosis, Coronary,Atherosclerosis, Coronary,Coronary Arteriosclerosis,Coronary Atherosclerosis,Left Main Coronary Artery Disease,Left Main Coronary Disease,Left Main Disease,Arterioscleroses, Coronary,Artery Disease, Coronary,Artery Diseases, Coronary,Atheroscleroses, Coronary,Coronary Arterioscleroses,Coronary Artery Diseases,Coronary Atheroscleroses,Left Main Diseases
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D015415 Biomarkers Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, ENVIRONMENTAL EXPOSURE and its effects, disease diagnosis; METABOLIC PROCESSES; SUBSTANCE ABUSE; PREGNANCY; cell line development; EPIDEMIOLOGIC STUDIES; etc. Biochemical Markers,Biological Markers,Biomarker,Clinical Markers,Immunologic Markers,Laboratory Markers,Markers, Biochemical,Markers, Biological,Markers, Clinical,Markers, Immunologic,Markers, Laboratory,Markers, Serum,Markers, Surrogate,Markers, Viral,Serum Markers,Surrogate Markers,Viral Markers,Biochemical Marker,Biologic Marker,Biologic Markers,Clinical Marker,Immune Marker,Immune Markers,Immunologic Marker,Laboratory Marker,Marker, Biochemical,Marker, Biological,Marker, Clinical,Marker, Immunologic,Marker, Laboratory,Marker, Serum,Marker, Surrogate,Serum Marker,Surrogate End Point,Surrogate End Points,Surrogate Endpoint,Surrogate Endpoints,Surrogate Marker,Viral Marker,Biological Marker,End Point, Surrogate,End Points, Surrogate,Endpoint, Surrogate,Endpoints, Surrogate,Marker, Biologic,Marker, Immune,Marker, Viral,Markers, Biologic,Markers, Immune
D017023 Coronary Angiography Radiography of the vascular system of the heart muscle after injection of a contrast medium. Angiography, Coronary,Angiographies, Coronary,Coronary Angiographies
D043203 1-Alkyl-2-acetylglycerophosphocholine Esterase A lipoprotein-associated PHOSPHOLIPASE A2 which modulates the action of PLATELET ACTIVATING FACTOR by hydrolyzing the SN-2 ester bond to yield the biologically inactive lyso-platelet-activating factor. It has specificity for phospholipid substrates with short-chain residues at the SN-2 position, but inactive against long-chain phospholipids. Deficiency in this enzyme is associated with many diseases including ASTHMA, and HYPERCHOLESTEROLEMIA. PAF Acetylhydrolase,Platelet-Activating Factor Hydrolase,Lipoprotein-Associated Phospholipase A(2),Lipoprotein-Associated Phospholipase A2,Lp-PLA(2),Lp-PLA2,PAF 2-Acetylhydrolase,PAF 2-Acylhydrolase,PAF Acetylhydrolase II,Platelet-activating Factor Acetylhydrolase IB,1 Alkyl 2 acetylglycerophosphocholine Esterase,2-Acetylhydrolase, PAF,Acetylhydrolase II, PAF,Acetylhydrolase, PAF,Esterase, 1-Alkyl-2-acetylglycerophosphocholine,Factor Hydrolase, Platelet-Activating,Hydrolase, Platelet-Activating Factor,Lipoprotein Associated Phospholipase A2,Lp PLA2,PAF 2 Acetylhydrolase,PAF 2 Acylhydrolase,Phospholipase A2, Lipoprotein-Associated,Platelet Activating Factor Hydrolase,Platelet activating Factor Acetylhydrolase IB

Related Publications

Tomotaka Dohi, and Katsumi Miyauchi, and Ryunosuke Ohkawa, and Kazuhiro Nakamura, and Shuta Thuboi, and Manabu Ogita, and Tadashi Miyazaki, and Akihisa Nishino, and Ken Yokoyama, and Takeshi Kurata, and Yutaka Yatomi, and Hiroyuki Daida
Increased plasma lipoprotein-associated phospholipase A2 levels are associated with coronary slow flow.
May 2020, BMC cardiovascular disorders,
Tomotaka Dohi, and Katsumi Miyauchi, and Ryunosuke Ohkawa, and Kazuhiro Nakamura, and Shuta Thuboi, and Manabu Ogita, and Tadashi Miyazaki, and Akihisa Nishino, and Ken Yokoyama, and Takeshi Kurata, and Yutaka Yatomi, and Hiroyuki Daida
Elevated Lipoprotein-Associated Phospholipase A2 Is Associated With Intracranial Atherosclerosis.
January 2022, Frontiers in neurology,
Tomotaka Dohi, and Katsumi Miyauchi, and Ryunosuke Ohkawa, and Kazuhiro Nakamura, and Shuta Thuboi, and Manabu Ogita, and Tadashi Miyazaki, and Akihisa Nishino, and Ken Yokoyama, and Takeshi Kurata, and Yutaka Yatomi, and Hiroyuki Daida
Lipoprotein-associated phospholipase A2 levels are associated with erectile dysfunction in patients without known coronary artery disease.
August 2015, Andrologia,
Tomotaka Dohi, and Katsumi Miyauchi, and Ryunosuke Ohkawa, and Kazuhiro Nakamura, and Shuta Thuboi, and Manabu Ogita, and Tadashi Miyazaki, and Akihisa Nishino, and Ken Yokoyama, and Takeshi Kurata, and Yutaka Yatomi, and Hiroyuki Daida
Role of lipoprotein-associated phospholipase A2 in atherosclerosis.
June 2008, Current atherosclerosis reports,
Tomotaka Dohi, and Katsumi Miyauchi, and Ryunosuke Ohkawa, and Kazuhiro Nakamura, and Shuta Thuboi, and Manabu Ogita, and Tadashi Miyazaki, and Akihisa Nishino, and Ken Yokoyama, and Takeshi Kurata, and Yutaka Yatomi, and Hiroyuki Daida
Regulation of lipoprotein-associated phospholipase A2 silencing on myocardial fibrosis in mice with coronary atherosclerosis.
June 2019, Biochemical and biophysical research communications,
Tomotaka Dohi, and Katsumi Miyauchi, and Ryunosuke Ohkawa, and Kazuhiro Nakamura, and Shuta Thuboi, and Manabu Ogita, and Tadashi Miyazaki, and Akihisa Nishino, and Ken Yokoyama, and Takeshi Kurata, and Yutaka Yatomi, and Hiroyuki Daida
Lipoprotein-associated Phospholipase A2 and Coronary Heart Disease.
January 2018, Current pharmaceutical design,
Tomotaka Dohi, and Katsumi Miyauchi, and Ryunosuke Ohkawa, and Kazuhiro Nakamura, and Shuta Thuboi, and Manabu Ogita, and Tadashi Miyazaki, and Akihisa Nishino, and Ken Yokoyama, and Takeshi Kurata, and Yutaka Yatomi, and Hiroyuki Daida
Lipoprotein-associated Phospholipase A2 in Coronary Artery Disease.
January 2022, Current topics in medicinal chemistry,
Tomotaka Dohi, and Katsumi Miyauchi, and Ryunosuke Ohkawa, and Kazuhiro Nakamura, and Shuta Thuboi, and Manabu Ogita, and Tadashi Miyazaki, and Akihisa Nishino, and Ken Yokoyama, and Takeshi Kurata, and Yutaka Yatomi, and Hiroyuki Daida
Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis.
November 2006, Arteriosclerosis, thrombosis, and vascular biology,
Tomotaka Dohi, and Katsumi Miyauchi, and Ryunosuke Ohkawa, and Kazuhiro Nakamura, and Shuta Thuboi, and Manabu Ogita, and Tadashi Miyazaki, and Akihisa Nishino, and Ken Yokoyama, and Takeshi Kurata, and Yutaka Yatomi, and Hiroyuki Daida
Modulation of oxidative stress, inflammation, and atherosclerosis by lipoprotein-associated phospholipase A2.
September 2012, Journal of lipid research,
Tomotaka Dohi, and Katsumi Miyauchi, and Ryunosuke Ohkawa, and Kazuhiro Nakamura, and Shuta Thuboi, and Manabu Ogita, and Tadashi Miyazaki, and Akihisa Nishino, and Ken Yokoyama, and Takeshi Kurata, and Yutaka Yatomi, and Hiroyuki Daida
Lipoprotein-associated phospholipase A2.
September 2006, Clinics in laboratory medicine,
Copied contents to your clipboard!